Trium Capital LLP Iveric Bio, Inc. Put Options Transaction History
Trium Capital LLP
- $350 Million
- Q3 2024
Put Options
1 transactions
Others Institutions Holding ISEE
# of Institutions
7Shares Held
250KCall Options Held
40KPut Options Held
0-
Monarch Partners Asset Management LLC187KShares$01.22% of portfolio
-
Pictet Asset Management Sa Geneva 73, V825KShares$00.0% of portfolio
-
Jefferies Group LLC New York, NY19.5KShares$00.0% of portfolio
-
Aevitas Wealth Management, Inc.17.8KShares$00.22% of portfolio
-
Endurance Wealth Management, Inc.1.5KShares$00.01% of portfolio
About IVERIC bio, Inc.
- Ticker ISEE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,078,000
- Description
- IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...